Botulinum Toxin A in Patients With Myofascial Pain Syndrome With and Without Zinc Supplementation
Myofacial Pain Syndrome, Botulinum Toxin
About this trial
This is an interventional treatment trial for Myofacial Pain Syndrome
Eligibility Criteria
Inclusion Criteria: Patients with myofascial pain Both genders males and females will be included. Ages from 17:50 Y General good health With complete dentation Exclusion Criteria: Subjected to irradiation in the head and neck area less than 1 year ago Edentulous patients Patient with recent trauma. Poor motivation. Active infection area related to masseter or temporalis. Patient with anti-tetanus vaccine 1-3 m before experiment
Sites / Locations
- Faculty of Dentistry
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Active Comparator
first group: (Control group)
second group. (intervention group)
EMG will be performed for masseter & temporalis muscles at the diagnosis appointment. Patients will recieve a daily placebo tablet in the morning after breakfast for 4 days prior to injections. Patients will receive a one-time treatment of 50 units of BoNT-A, the dose will be injected into the bilateral masseter muscles (16.7 units each masseter) and 1/3 into the bilateral temporalis (8.3 units each temporalis). Follow up will be performed using EMG for the masseter and temporalis muscles 4 months after the BoNT-A injection.
EMG will be performed for masseter & temporalis muscles at the diagnosis appointment. Patients will receive a daily zinc supplement tablets of 50 mg in the morning after breakfast for 4 days prior to injections. Patients will receive a one-time treatment of 50 units of BoNT-A, the dose will be injected into the bilateral masseter muscles (16.7 units each masseter) and 1/3 into the bilateral temporalis (8.3 units each temporalis). Follow up will be performed using EMG for the masseter and temporalis muscles 4 months after the BoNT-A injection.